Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
Gilead settles on twice-yearly treatment partner for lenacapavir
Gilead has chosen which of two assets to pair with lenacapavir moving forward, with plans to share more details on the winner next year.
Darren Incorvaia
Oct 30, 2025 6:37pm
Kite puts $1.64B on the line for Pregene's in vivo CAR-Ts
Oct 16, 2025 4:56pm
Evoq Therapeutics signs on with Sanofi in $500M partnership
Oct 16, 2025 10:25am
Gilead, Arcus keep TIGIT dream alive with 27-month OS data
Oct 13, 2025 7:05am
Gilead pumps up virology pipeline with drug transporter deal
Sep 29, 2025 10:35am
One-third of data collected in trials may be unnecessary: study
Sep 19, 2025 11:01am
